SCHEMBL2326653

SCHEMBL2326653

COc1ccc(C(=N)NO)cc1F

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.57
LMNA P02545 1/20 0.57
MAPK1 P28482 1/20 0.57
RAB9A P51151 1/20 0.57
TAS1R3 Q7RTX0 1/20 0.47
TAS1R1 Q7RTX1 1/20 0.47
KCNQ3 O43525 1/20 0.43
KCNQ2 O43526 1/20 0.43
MEP1B Q16820 1/20 0.43
TUBB1 Q9H4B7 3/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
ALDH1A1 P00352 2/20 0.41
PDE4A P27815 1/20 0.41
PDE4B Q07343 1/20 0.41
PDE4C Q08493 1/20 0.41
PDE4D Q08499 1/20 0.41
MAPT P10636 1/20 0.41
ACHE P22303 1/20 0.41
KDM1A O60341 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27207679 0.86 HTT (0.41) HTTLMNAMAPK1RAB9AALDH1A1
SCHEMBL4221619 0.84 CYP2C9 (0.55) LMNAMAPK1MEN1KMT2AALDH1A1
SCHEMBL2326796 0.80 EPHX2 (0.49) HTTLMNAMAPK1RAB9A
SCHEMBL429692 0.79 LMNA (0.61) HTTLMNAMAPK1RAB9ATAS1R3
SCHEMBL23578552 0.79 THRA (0.49) HTTLMNARAB9AMEN1KMT2A
SCHEMBL29973327 0.79 THRA (0.49) HTTLMNARAB9AMEN1KMT2A
SCHEMBL17396232 0.78 RAB9A (0.46) HTTLMNAMAPK1RAB9ATAS1R3
SCHEMBL640675 0.77 CES2 (0.50) RAB9ATAS1R3TAS1R1KCNQ3KCNQ2
SCHEMBL30506215 0.77 CES2 (0.50) RAB9ATAS1R3TAS1R1KCNQ3KCNQ2
Hydrochloric Acid SCHEMBL9741360 0.77 PRSS1 (0.59) HTTLMNAMAPK1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10118930-B2 Piperidinylpyrazolopyrimidinones and their use BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-11-06 US disclosed
US-20170334917-A1 PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-11-23 US disclosed
EP-2356112-A1 HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS Bayer Schering Pharma Aktiengesellschaft (DE) 2011-08-17 EP disclosed
WO-2010054764-A1 HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10118930-B2 Piperidinylpyrazolopyrimidinones and their use HAMP, SERPINC1, PRSS8 HTT 249/4885LMNA 2585/4885MAPK1 3105/4885
US-20170334917-A1 PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE HAMP, SERPINC1, PRSS8 HTT 249/4885LMNA 2585/4885MAPK1 3105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.